Loading…
Loading…
MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.
BALTIMORE, MD / ACCESS Newswire / November 5, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCID:RGBP, RGBPP), a biopharma developer that seeks to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. The Goldman report carries a price target.
Company Set to Make Migration from Preclinical to Clinical Stage BALTIMORE, MD / ACCESS Newswire / July 17, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCPK:RGBP), a developer of innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology segment. The Goldman report carries a price target.
Targeting Transformative Solutions for Aplastic Anemia and Beyond SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate ™ , the company's innovative stem cell-derived therapy, which has already received FDA clearance. While the initial focus is on treating aplastic anemia, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in a market poised for significant growth.
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Regen BioPharma, Inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , April 2, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on April 4, 2024 (https://emerginggrowth.com/conference/).
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Jan. 8, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on January 10, 2024 (https://emerginggrowth.com/conference/).
SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6.